O-linked carbohydrate-modified insulin analogues
An insulin analogue comprises an insulin B-chain polypeptide modified with an O-linked monosaccaride pyranoside adduct at the side chain of residue B27 or an O-linked monosaccaride pyranoside adduct at the side chain of residue B30, or both, where the positions are recited relative to human insulin. The monosaccaride may be a manopyranoside, an N-acetyl-galactopyranoside, or a glucopyranoside. The insulin analogue may additionally comprise containing a foreshortened B-chain polypeptide lacking residues B1-B3, an extension of 1 or 2 Glu residues on the carboxy terminal end of the B-chain polypeptide, an extension of ornithine at the carboxy-terminal end of the B-chain, the substitutions Lys at position B28 and Pro at position B29, an ornithine substitution at position B29, or combinations thereof. The analogue may be an analogue of a mammalian insulin, such as human insulin. A method of treating a patient comprises administering a physiologically effective amount of the insulin analogue.
1. An insulin analogue comprising an insulin B-chain polypeptide modified with at least one of an O-linked monosaccaride pyranoside adduct at the side chain of residue B27 and an O-linked monosaccaride pyranoside adduct at the side chain of residue B30, relative to human insulin.
2. The insulin analogue of claim 1 , wherein the at least one monosaccaride is selected from the group consisting of a manopyranoside, an N-acetyl-galactopyranoside, and a glucopyranoside.
3. An insulin analogue of claim 2 , wherein the at least one monosaccaride adduct is located at position B27.
4. An insulin analogue of claim 3 , wherein the at least one monosaccaride O-linkage has an alpha configuration.
5. An insulin analogue of claim 3 , wherein the at least one monosaccaride O-linkage has a Beta configuration.
6. An insulin analogue of claim 2 , wherein the at least one monosaccaride adduct is at position B30.
7. An insulin analogue of claim 6 , wherein the monosaccaride O-linkage has an alpha configuration.
8. An insulin analogue of claim 6 , wherein the monosaccaride O-linkage has a Beta configuration.
9. An insulin analogue of claim 6 , additionally comprising a monosaccaride adduct located at position B27.
10. An insulin analogue of claim 2 , wherein the at least one monosaccaride is linked to the side-chain oxygen atom of Threonine.
11. The insulin analogue of claim 2 , wherein the insulin analogue additionally comprises the substitutions Lys B28 and Pro B29 .
12. An insulin analogue of claim 2 , wherein the B chain is additionally extended by Glu B31 and optionally Glu B32 .
13. An insulin analogue of claim 2 , wherein the insulin analogue additionally comprises Orn B29 .
14. An insulin analogue of claim 2 additionally comprising Histidine substitutions at positions A4 and A8 and a Glycine substitution at position A21.
15. An insulin analogue of claim 2 , comprising a B chain polypeptide having the polypeptide sequence of SEQ ID NO: 7 and optionally an A chain polypeptide sequence of SEQ ID NO: 51.
16. An insulin analogue of claim 2 , wherein the analogue is an analogue of a mammalian insulin.
17. A method of lowering the blood sugar of a patient, the method comprising administering a physiologically effective amount of an insulin analogue or a pharmaceutically acceptable salt thereof to the patient, wherein the insulin analogue or a pharmaceutically acceptable salt thereof contains a B-chain polypeptide modified by at least one of an O-linked monosaccharide at position B27 and an O-linked monosaccharide at position B30.
18. The method of claim 17 , wherein the at least one monosaccharide is selected from the group consisting of a manopyranoside, an N-acetyl-galactopyranoside, and a glucopyranoside.
19. The method of claim 18 , wherein the B chain is additionally extended by Glu B31 and optionally Glu B32 .
20. A peptide containing an N-terminal glycine and one or two O-linked monosaccharide adducts selected from the group consisting of SEQ ID NOS: 54, 62 and 63.